# NasaClip

Easy Treatment for Nosebleeds: An ER doctor & mom-designed device

- Canonical URL: https://wefunder.com/nasaclip
- Entity ID: wefunder:company:163555
- Last updated: 2026-06-12T05:01:17Z
- Generated at: 2026-06-13T04:29:22Z

## Quick facts
- Customers: Disney, Doctors on Duty, Adventist Healthcare & University of Maryland Medical System
- Backed by VCs: Blue Cross Blue Shield MA, Conscious Venture Partners, Portfolia, The Impact Seat
- Awarded National Science Foundation Innovation Research Phase I grant funding ($256K value)
- 5 patents granted & 2 pending; FDA-registered, Class I 510(k)-exempt device
- CNBC, MSNBC, ABC Good Morning, iHeartRadio & Ebony features
- Led by top physicians and execs from Duke, Dartmouth, Oatly, Cardinal Health, and Johnson & Johnson
- Launching Amazon D2C channel in Q4 24 to reach 200M Americans who suffer from nosebleeds
- Pioneering a massive $5B market for nosebleed care & $43B drug-delivery platform market

## Active fundraises
- wefunder:fundraise:123346: 4(a)(6) successful (USD)
- wefunder:fundraise:123345: 4(a)(6) successful (USD)

## Story
NasaClip is an easy treatment for nosebleeds, driving innovation in a $5B market with a doctor-designed, hands-free solution to an incredibly disruptive and common problem—affecting 60% of the population and leading to over 500,000 ER visits each year.Designed and led by ER physician Dr. Elizabeth Clayborne along with experts and top executives from Duke, Dartmouth, Oatly, and Johnson & Johnson, our early traction shows growing demand for a fast, safe, and easy treatment for nosebleeds in both medical and consumer sectors.Backed by notable investors including Blue Cross Blue Shield Massachusetts, TEDCO, Conscious Venture Partners, Portfolia, Women of Color in Pharma, and The Impact Seat, as well as funding from the National Science Foundation, NasaClip is on track to becoming a must-have in hospitals, homes, and first aid kits everywhere, reducing the stress of nosebleeds and improving quality of life for millions. Nosebleeds are extremely common, yet stressful and often mismanaged. Nosebleeds can happen at any time - at school, during dinner, aboard a plane, while playing sports, or at work. Children aged 2-10 and older adults 55-80 on blood thinner medications are particularly susceptible. Most people don’t know how to properly treat a nosebleed and they turn to ineffective fixes such as tissues, gauze, or pinching the nose in the wrong place. These methods rarely work and can lead to more mess and aggravation, eventually ending with a time-consuming and costly trip to the ER.Once at the ER, healthcare professionals lack a quick and easy way to treat nosebleeds, further compounding the stress and chaos caused by this simple injury.  Effective nosebleed care is often out of reach where it's needed most, and many people live in fear of not being able to stop the bleeding quickly and discreetly. An easily treatable issue can quickly become a debilitating problem, disrupting daily life and causing unnecessary anxiety.Introducing NasaClip. We’re pioneering the $5B nosebleed care market with a hands-free, fast-acting device that anyone can use, wherever they are.Unlike rough tissues and bulky gauze, NasaClip combines comfortable, perfectly placed pressure with sponges that can deliver medications to stop bleeding quickly and cleanly. No stress, no mess—just fast relief. NasaClip goes beyond convenience—it's a proven, ER doctor-designed device that brings medical-grade care for all ages to everyday situations, for everyone involved.Whether at home, in the ER, or on the go, NasaClip provides quick and effective relief, taking the guesswork out of stopping nosebleeds.NasaClip’s multi-patented, unique design and widespread applicability position us to capture a significant share of this massive market.On the medical side, our serviceable market includes 400,000 public and private hospital sites, long term care centers, schools, and sports stadiums. On the consumer side, our serviceable market includes 190,000 pharmacies and convenience stores, in addition to direct-to-consumer sales to millions of Americans via Amazon and our Shopify-powered ecommerce store. With over $100K in revenue, 300 locations, and a $1.7M sales pipeline within months of our soft launch, we’re gaining traction in medical and B2B accounts. Target B2B accounts and examples of organizations who could benefit from our fast and effective nosebleed care include Mount Sinai, Atrium Health, JetBlue, Delta, and the Miami Dolphins, in addition to wholesale to pharmacy chains and other retail outlets. By the end of 2024, we will expand our reach on leading ecommerce platforms like Amazon and Shopify, as well as a retail launch anticipated in 2025.NasaClip is led by Dr. Elizabeth Clayborne, a practicing ER physician with firsthand experience treating countless nosebleeds and 20K+ patients during her 10+ year tenure, as well as Romil Patel, a seasoned B2B and consumer go-to-market expert. Together, with a team of experts from Johnson & Johnson, Cardinal Health, and Oatly, we’ve built NasaClip into a market-ready solution with both medical validation and consumer appeal.Sales are driven by single use, reusable kits, and refill packs. With margins averaging 75% and recurring revenue from restocking, we’ve established a strong foundation for long-term growth and profitability.NasaClip’s device has clinical applications beyond nosebleed care. We’ve received National Science Foundation (NSF) Small Business Innovation Research Programs (SBIR) Phase I grant funding, and we are pursuing additional funding from the National Institute of Health to research the development of a novel intranasal drug delivery platform leveraging our device. Early indicators of success mean we are now pursuing the next stage of SBIR funding to further develop this platform for use with drugs such as Naloxone, benzodiazepines, analgesic medication, and migraine medication - serving an even broader $43B market.We believe NasaClip offers significant exit potential across multiple sectors. As a first-of-its-kind, physician-designed device for nosebleed management, it is an attractive acquisition target for consumer device manufacturers, medical distributors, drug delivery companies, and retail chains. Strategic partners in healthcare, retail, or MedTech could leverage our strong IP portfolio and growing market presence to expand their product lines, enhance their offerings, and capture a share of this market which lacks effective and convenient solutions.NasaClip is a no-brainer for millions of hospitals, schools, and homes. Venture investors including The Blue Cross Blue Shield of Massachusetts, Portfolia, and Conscious Venture Partners have invested and now, we’re inviting our patients, day-one supporters, future users, and community to invest on the same terms so we can bring NasaClip to the mass market.Just as there is a go-to brand for wound care, NasaClip is poised to become the trusted name for nosebleed management in every hospital, first aid kit, and medicine cabinet worldwide. Join us in building the doctor’s choice for nosebleed care—an iconic brand loved by caregivers and parents everywhere.Invest in NasaClip today.

## FAQ
1. **Hello NasaClip Team, I’m Zac Stahlhut with D3VC, where we focus on equity crowdfunding investments. We find your offering compelling and are eager to learn more about your business trajectory. Could you provide an update on your progress toward the $30,000 revenue target? Addi...**
   - Hi Zac. Appreciate your interest in NasaClip! As an update we achieved 88% of our Q3 revenue target ($32,422). A couple of the expected Q3 B2B orders will now occur in Q4. Currently, 70% of sales come from B2B customers and 30% from DTC. With the launch of our new consumer product line we expect revenue to stabilize to a 65% (B2B) /35% (DTC) split in the coming years. Example of B2B customers include hospital systems, urgent care centers, outpatient clinics, airplanes, cruises, and retail. As...
2. **Hi Elizabeth, thank you for the detailed response. We’re curious to learn more about your pricing strategy—have you conducted customer research to validate your current price point and gauge consumer willingness to pay? Additionally, as you establish brand presence in an emerg...**
   - Hi Zac, we conducted over 150+ customer interviews with physicians, consumers and key decision makers across various B2B medical settings and consumers in e-commerce markets. These interviews along with our competitor pricing analysis helped triangulate a price range and customer willingness to spend. Yes, we have plans to experiment with low cost marketing campaigns to encourage broader adoption. Happy to jump on call if you would like more details.
3. **What will you be selling these to companies for and what is the cost to manufacture? What is your exit plan? Sell company or IPO and by when? - Also, when do you plan to be profitable?**
   - Hi Yaccov, around 70% of our business is B2B (hospitals, urgent cares, schools, sports, travel, events) and 30% DTC, our Amazon channel just went live. COGS are currently around $4.50 but that is at 10,000 unit productions so as we scale they will improve. Our likely exit will more likely be acquisition. We think we can be profitable in 1-2 years depending on sales. I hope that answered your questions!
4. **I have already invested. When can I reinvest?**
   - Hi Mario, our crowdfunding portion is closed at this point. If we open another round we will let you know. We do have institutional investing open for people who can invest $100K+, if that interests you please email me at eclayborne@nasaclip.com

## Team
- Elizabeth Clayborne (Co-Founder & CEO)
- Romil Patel (Co-Founder & CFO)
- Dr. Neal Sikka (Co-Founder)
- Mike Russell (Head of Sales)
- Kris Smith Purnell (Head of Operations)
- Betsy Bluestone (Advisor, Consumer)
- David Giarracco (Advisor, Commercial)
- Maurice Reid (Lead Investor, Board Member)

## Recent posts
- 🚨 Last Chance Alert! 🚨 NasaClip closing in 1 day! (2025-04-07T20:43:48Z)
- Wefunder closing April 8th, only 5 days left to (re)invest in NasaClip! (2025-04-03T18:08:59Z)
- NasaClip honored at the Baltimore Museum of Industry (2025-03-26T13:54:20Z)
- Dr. Liz on USPTO Panel 3/27! (2025-03-18T15:33:08Z)
- NasaClip going public on 3/12, (re)invest now to ensure your spot! (2025-03-03T17:37:47Z)
- Dr. Clayborne Presenting at CWRU Veal Institute for Entrepreneurship today (2/21) (2025-02-21T16:09:56Z)
- > $235K invested on Wefunder!! 5 Reasons to (Re)Invest in NasaClip (2025-02-20T15:58:59Z)
- INNOVATE Washington Unboxing! (2025-01-30T18:34:02Z)
- From Chaos to Calm: a lifesaver for me and my daughter! 🩸 (2025-01-24T20:48:18Z)
- Dr. Liz gets 1st Place in Market Pulse Pitch! (2025-01-14T20:45:24Z)
- A Look Back at 2024: Wrapping Up a Milestone Year 🎆 (2025-01-02T15:10:59Z)
- We’re Featured on AFROTECH (again)! 🚀 (2024-12-22T13:32:53Z)
- We’re officially an American Red Cross Supplier! (2024-12-17T19:55:52Z)
- ‘Tis the Season to Transform Nosebleed Care! 👃❄️ (2024-12-13T15:00:09Z)
- Missed Our Growth Strategy Webinar? Replay Available Now! 📈🚀 (2024-12-11T01:22:51Z)

## Q&A
- Q: Where can I buy a NasClip as my son has awful nosebleeds? Is there a direct site for the product as sellers are seemingly exploiting the public with exorbitant pricing on Amazon? Please advise, as this product could help my son tremendously. I would have invested had I been aware of the crowdfunding campaign.
- Q: How can I invest/support the growth in NasaClip?
- Q: How have you addressed ensuring insurance coverage of Nasaclip? Would this product simple be a 'medical supply' thatt the insurance company would automatically cover, like gauze or band aids, or is it considered a specific medical device that insurance would not specifically cover? What is your price point for hospitals/urgent care?
- Q: I have already invested. When can I reinvest?
  - A: Hi Mario, our crowdfunding portion is closed at this point. If we open another round we will let you know. We do have institutional investing open for people who can invest $100K+, if that interests you please email me at eclayborne@nasaclip.com
- Q: Why your monthly expenses are so high? How many people are paid in the company?
- Q: What will you be selling these to companies for and what is the cost to manufacture? What is your exit plan? Sell company or IPO and by when? - Also, when do you plan to be profitable?
  - A: Hi Yaccov, around 70% of our business is B2B (hospitals, urgent cares, schools, sports, travel, events) and 30% DTC, our Amazon channel just went live. COGS are currently around $4.50 but that is at 10,000 unit productions so as we scale they will improve. Our likely exit will more likely be acquisition. We think we can be profitable in 1-2 years depending on sales. I hope that answered your questions!
- Q: Hi Elizabeth! I run a newsletter that is hyper-focused on the crowdfunding industry and goes out to nearly 5,000 retail investors each week. I'm interested by your raise and would love to chat for a potential story on my blog (no cost, this is purely editorial content). Reach out to hellocrowdscale@gmail.com if you'd like to connect. Blog for reference: https://crowdscale.beehiiv.com/
- Q: Thanks, Elizabeth! We’d love the opportunity to discuss your go-to-market and scaling strategies in more detail. Please feel free to reach out to me at zstahlhut@d3vc.ai to coordinate a time for a call with myself and other members of our team. We’re looking forward to continuing the conversation!
- Q: Hi Elizabeth, thank you for the detailed response. We’re curious to learn more about your pricing strategy—have you conducted customer research to validate your current price point and gauge consumer willingness to pay? Additionally, as you establish brand presence in an emerging category, do you plan to explore strategies for encouraging broader adoption? Thanks again!
  - A: Hi Zac, we conducted over 150+ customer interviews with physicians, consumers and key decision makers across various B2B medical settings and consumers in e-commerce markets. These interviews along with our competitor pricing analysis helped triangulate a price range and customer willingness to spend. Yes, we have plans to experiment with low cost marketing campaigns to encourage broader adoption. Happy to jump on call if you would like more details.
- Q: Hello NasaClip Team, I’m Zac Stahlhut with D3VC, where we focus on equity crowdfunding investments. We find your offering compelling and are eager to learn more about your business trajectory. Could you provide an update on your progress toward the $30,000 revenue target? Additionally, which customer segments—direct-to-consumer or institutional clients—are currently driving your sales? What pricing strategies are you employing for individual consumers compared to organizations? Lastly, in light of potential competition, how are you safeguarding your market position against attempts to redesign your product to bypass your patent protections, and what measures have you taken to ensure your patents are robust and difficult to circumvent? Thank you!
  - A: Hi Zac. Appreciate your interest in NasaClip! As an update we achieved 88% of our Q3 revenue target ($32,422). A couple of the expected Q3 B2B orders will now occur in Q4. Currently, 70% of sales come from B2B customers and 30% from DTC. With the launch of our new consumer product line we expect revenue to stabilize to a 65% (B2B) /35% (DTC) split in the coming years. Example of B2B customers include hospital systems, urgent care centers, outpatient clinics, airplanes, cruises, and retail. As a premium product in an emerging product category, we employ a hybrid cost-plus and competition based pricing strategy for both B2B and DTC channels. We run regular competitor surveillance to identify any copycat products infringing on NasaClip IP. If that scenario arises, we notify our legal team so they take the appropriate action. We have obtained patent protection on several iterations of the product to ensure our patents are robust and difficult too circumvent. We also have PCT (international patent application) which we specifically designate high counterfeiting countries like China, Mexico and India. Our legal team is also well connected in those countries to undertake an enforcement action. In addition, we have domestic and international trademark protection for our slogans and brand. Please let us know if you have any other questions.